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Abstract 
Calciphylaxis is a vascular calcification-cutaneous necrosis syndrome, usually seen in 
patients with end-stage renal disease and secondary hyperparathyroidism. We report a 
57-year-old polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, 
and skin changes (POEMS) syndrome patient complicated with extensive skin ulcers due 
to calciphylaxis. He first noted a painful cutaneous ulcer on his left thigh, and then skin 
lesions rapidly worsened, resulting in multiple intractable ulcers with gangrene on his 
legs and trunk in a few months. Serum vascular endothelial growth factor (VEGF) was 
markedly elevated. Biopsy samples from his skin ulcers showed the deposition of calcium 
in the medial layer of cutaneous vessels, this finding being compatible with calciphylaxis. 
This is the second reported case with POEMS syndrome complicated with calciphylaxis. 
Both patients had no evidence of renal failure, hyperparathyroidism, or clotting 
disorders. The pathogenic link between POEMS syndrome and calciphylaxis is still 
unclear, but VEGF is known to regulate vascular calcification, in cooperation with bone 
morphogenetic proteins. Further, corticosteroid and several proinflammatory cytokines 
activate nuclear factor-κB pathway, known as the final common pathway leading to 
vascular calcification. Taken together, we consider that POEMS syndrome can be an 
independent risk condition for calciphylaxis. 
 
Introduction 
Calciphylaxis is a rare, but life-threatening disease characterized by progressive 
cutaneous necrosis and ulceration secondary to small- and medium-sized vessel  
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calcification [1–3]. It is also known as the ‘vascular calcification-cutaneous necrosis 
syndrome’. End-stage renal disease and hyperparathyroidism have been considered as 
major causes for calciphylaxis, but many other conditions can be associated with 
calciphylaxis [1–4]. Chronic inflammation and prolonged corticosteroid administration 
have recently been reported as calciphylaxis-inducible conditions in non-uremic cases [5, 
6], although their precise mechanism has been poorly understood. Many kinds of 
management for calciphylaxis have been tried [1–3], but there is still no effective 
treatment available. The main cause of death in calciphylaxis patients is fatal bacterial 
infection due to the destruction of the cutaneous defense system [1–3]. The total 
mortality rate has been reported to range from 60–80% [1]. 
On the other hand, polyneuropathy, organomegaly, endocrinopathy, monoclonal 
gammopathy, and skin changes (POEMS) syndrome is a rare multisystem disorder caused 
by plasma cell dyscrasia, often requiring long-term corticosteroid therapy [7]. Vascular 
endothelial growth factor (VEGF) has been implicated in the pathogenesis of POEMS 
syndrome and the serum level of VEGF is parallel to the disease activity [8–10]. As 
included in the disease acronym, skin changes are one of the major features in POEMS 
syndrome; they are hyperpigmentation, skin thickening, hypertrichosis, cherry angioma, 
white nails, clubbing, flushing and peripheral cyanosis [7]. To our knowledge, however, 
only one case with POEMS syndrome has been reported to be associated with 
calciphylaxis [11]. 
Here we report a Japanese patient who developed calciphylaxis 11 years after the onset 
of POEMS syndrome. The pathogenic link between POEMS syndrome and calciphylaxis 
is briefly discussed.  
Case Report 
A 57-year-old male with an 11-year history of POEMS syndrome was admitted to our hospital 
because of painful skin ulcers and edema. The first sign of POEMS syndrome was lower limb weakness 
and numbness. The diagnosis of POEMS syndrome had been made on the basis of polyneuropathy, 
lymphadenopathy, gynecomastia, monoclonal gammopathy (IgG λ type), skin pigmentation and 
hypertrichosis with elevated serum VEGF levels. Biopsy specimens from his sural nerve tissue showed 
axonal degeneration with myelin ovoid and endoneurial edema, in agreement with the histological 
diagnosis of polyneuropathy associated with POEMS syndrome. Cervical lymph node biopsy showed 
the finding compatible with hyaline vascular type Castleman’s disease. Bone survey did not reveal any 
sclerotic or lytic bone lesions, and bone marrow aspiration showed normal or slightly hypercellular 
marrow without plasma cell proliferation. In spite of corticosteroid therapy with additional intravenous 
immunoglobulin therapy or oral azathioprine therapy, the disease gradually worsened. The patient 
refused treatment with conventional chemotherapy or high-dose melphalan chemotherapy combined 
with peripheral blood stem cell transplantation for plasma cell dyscrasia. 
He first noted an ulcer on his left thigh 6 months before the present admission. The skin lesion was 
resistant to conventional skin care and treatment, and worsened gradually. He showed severe and 
painful ulcers with gangrene on his bilateral thighs on admission (fig. 1a). The circumference of each 
ulcer seemed to be ischemic. Marked pitting edema was seen on his trunk and extremities. Laboratory 
examination showed slight leukocytosis and hypoalbuminemia (table 1). Serum calcium concentration 
revised with albumin level, phosphorus concentration and parathyroid hormone level showed normal 
values. The concentration of serum VEGF was markedly higher than observed earlier (table 1, fig. 2). 
Though immunological examination showed slightly elevated anti-cardiolipin antibody levels, lupus 
anticoagulant level was normal. Protein C and protein S, as well as other coagulation regulatory factors, 
were within normal levels. Microbial examination of the ulcerous tissue was negative for any 
microorganism. Disseminated calcification of vascular walls, especially in cutaneous vessels, was 
demonstrated with X-ray photography (fig. 3a) and computed tomography (CT) (fig. 3b). No 
calcification was evident on the X-ray photograph of the same site 2 years before the present admission. 
Thoracic CT demonstrated left pleural effusion. A biopsy specimen from the skin ulcer on his left thigh 
proved proliferation of endothelial cells and calcification in several cutaneous small-sized vessels (fig.  
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1c, d). According to clinical features, radiographic and histological findings, the diagnosis of 
calciphylaxis was confirmed.  
To prevent the progression of POEMS syndrome and calciphylaxis, combination therapy using 
melphalan (0.22 mg/kg/day, for 4 days), dexamethasone (40 mg/day, for 4 days) and the anti-VEGF 
agent, thalidomide (100 mg/day, daily use), was started. The serum VEGF concentration drastically 
decreased after the initiation of this combination therapy, but the calciphylaxis remained 
uncontrollable. His skin ulcerations extended to the bilateral legs and trunk in a few months (fig. 1b). 
Additional hyperbaric oxygen (HBO) therapy and bisphosphonates failed to repress calciphylaxis. He 
died of sepsis 17 months after the onset of calciphylaxis. 
Discussion 
Most cases with calciphylaxis reported so far have been associated with end-stage renal 
disease and secondary hyperparathyroidism [1–3]. However, there is growing evidence 
that this entity is associated with several non-uremic diseases such as malignancy, 
alcoholic liver disease, collagen-vascular diseases, diabetes and inflammatory bowel 
disease [1–4]. This clearly indicates that the etiology of calciphylaxis is multifactorial. The 
possible risk conditions or trigger factors for calciphylaxis in non-uremic diseases include 
chronic inflammatory state, systemic hypercoagulable state, and chronic 
immunosuppressive state [1–4]. 
To date, coexistent POEMS syndrome and calciphylaxis has been reported only in one 
patient [11]. De Roma et al. reported a 46-year-old Italian woman who developed 
calciphylaxis 34 months after the diagnosis of POEMS syndrome. Both the case of De 
Roma et al. and ours lacked the well-known risk conditions such as renal failure, 
hyperparathyroidism, or clotting disorders. Although the VEGF values were not 
described in that case, a high dose of corticosteroid was used [11]. These cases indicate 
that POEMS syndrome can be an independent risk condition for the development of 
calciphylaxis in certain circumstances. 
Vascular calcification is thought to result from imbalance between bone deposition 
and resorption [12, 13]. Various bone-regulating proteins are involved in the process of 
vascular calcification [12, 13]. RANKL (receptor activator of nuclear factor-κB (NF-κB) 
ligand) and its antagonist, osteoprotegerin (OPG), play a critical role in bone remodeling 
[12, 13]. The activation of RANK-mediated NF-κB pathway causes osseous mineral loss 
and extraosseous (vascular) mineral deposition. The pathogenic link between 
calciphylaxis and POEMS syndrome calls for further discussion. Chronic deregulation of 
VEGF and proinflammatory cytokines has been implicated in the pathogenesis of POEMS 
syndrome [7]. In particular, the level of serum VEGF is widely used as a marker of disease 
activity in POEMS syndrome [8–10]. Interestingly, it is reported that VEGF regulates 
calcification in cultured vascular smooth muscle cells, or other type of cells, in 
cooperation with bone morphogenetic proteins (BMPs) [14, 15]. Furthermore, 
corticosteroid, as well as parathyroid hormone, is known to activate RANK-mediated NF-
κB pathway and to inhibit OPG [12].Thus, a long-term corticosteroid administration is 
likely to promote osseous mineral loss and vascular calcification. Several proinflammatory 
cytokines, namely interleukin-1 and tumor necrosis factor-α, may promote vascular 
calcification by activating RANK-mediated NF-κB pathway [12]. Taken together with 
these evidences, it is very likely that POEMS syndrome is a possible risk condition for 
calciphylaxis. 
In conclusion, we report the second case of POEMS syndrome complicated with 
calciphylaxis. The precise causes for calciphylaxis in our patient remain unsolved, but we  
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speculate that the sustained elevation of serum VEGF levels and the long-term 
administration of corticosteroids could contribute to the development of calciphylaxis. 
Our trial with an anti-VEGF agent failed to control calciphylaxis, but the initiation of 
anti-VEGF therapy in the earlier stage of the disease could prevent or delay the 
development of calciphylaxis. 
 
 
 
Table 1. Laboratory findings on admission 
Variable  Value (normal range) 
White blood cell count, ×10
3/μl 11.82  (2.97–9.13) 
Neutrophils, %  095.0 (28.0–78.0) 
Hemoglobin, g/dl  014.9 (12.9–17.4) 
Platelet, ×10
4/μl  026.6 (14.3–33.3) 
C-reactive protein, mg/dl  00.20 (<0.10) 
Albumin, g/dl  002.9 (4.2–5.1) 
Urea nitrogen, mg/dl  00.24 (9–22) 
Creatinine, mg/dl  00.58 (0.60–1.00) 
Calcium, mg/dl  007.6 (8.6–10.1) 
Corrected calcium, mg/dl  008.7 (8.7–9.9) 
Phosphate, mg/dl  003.6 (2.2–4.1) 
PT (INR)  01.02 (0.85–1.15) 
APTT, s  028.6 (23.0–38.0) 
Protein C, %  00.82 (70–140) 
Protein S, %  078.8 (60.0–150.0) 
Lupus anticoagulant (ratio)  01.05 (0.00–1.29) 
aCL/β2GPI antibody, U/ml  004.0 (0.0–3.4) 
intact PTH, pg/ml  031.8 (10.0–65.0) 
PTHrP, pmol/l  0<1.0 (0.0–1.1) 
Prolactin, ng/ml  021.2 (1.5–9.7) 
Estradiol, pg/ml  00.15 (20–59) 
Cortisol, μg/dl  002.5 (5.0–15.0) 
Renin, ng/ml/h  000.3 (0.2–3.1) 
Aldosterone, pg/ml  <25.0 (35.7–240.0) 
VEGF, pg/ml  4,240 (0–115) 
IL-6, pg/ml  0.827 (<2.41) 
PT = prothrombin time; APTT = activated partial thromboplastin time; aCL/β2GPI = anticardiolipin-
β2 glycoprotein; PTH = parathyroid hormone; PTHrP = parathyroid hormone related peptide; VEGF = 
vascular endothelial growth factor; IL-6 = interleukin-6. 
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Fig. 1. Calciphylaxis-induced skin changes at admission (a left thigh). A spread of the ulcer had 
expanded to the bilateral legs and trunk in a few months (b lower trunk and bilateral thighs). Histology 
of biopsy specimen from the ulcer on the left thigh showed classic findings of calciphylaxis including 
intimal hyperplasia with local fat necrosis (c) and calcium deposits (c, d arrowheads) in the media of 
small- and medium-sized arteries. c Hematoxylin-eosin stain; d von Kossa stain; scale bar = 100 μm. 
 
 
 
Fig. 2. Clinical time course. Corticosteroid, azathioprine and IVIg reduced serum VEGF levels and 
suppressed the disease activity of POEMS syndrome transiently, but the disease relapsed. The value of 
serum VEGF dramatically increased at the diagnosis of calciphylaxis. After treatment with M-Dex and 
thalidomide, the VEGF levels decreased. mPSL = High-dose intravenous methylprednisolone (1 g/day, 
3 days); PSL = oral prednisolone (20–60 mg/day); IVIg = intravenous immunoglobulin (0.4 g/kg/day, 
5 days); M-Dex = melphalan (0.22 mg/kg/day) and dexamethasone (40 mg/day, day 1–4). 
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Fig. 3. Soft-tissue X-ray showed some calcified small- and medium-sized arterioles (a left wrist, 
arrowheads), and computed tomography (CT) also showed multiple subcutaneous and intramuscular 
calcifications (b bilateral thigh, arrowheads). 
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